Drug Trial Radar · NCT07738822
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2029
Study completion Jan 2031
Sponsor
- Lead sponsor
- Cullinan Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.
Conditions
- Immune Thrombocytopenia (ITP)
- Warm Autoimmune Hemolytic Anemia (WAIHA)
Interventions
Velinotamig specified dose on specified days.Drug
Velinotamig is an engineered bispecific antibody directed against BCMA and CD3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cullinan Investigative Site
Webster, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.